Crescita Therapeutics Company Executives
| CTX Stock | CAD 0.47 0.02 4.08% |
Crescita Therapeutics employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Crescita Therapeutics' management performance can provide insight into the firm performance.
Crescita |
Crescita Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0933) % which means that it has lost $0.0933 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1852) %, meaning that it generated substantial loss on money invested by shareholders. Crescita Therapeutics' management efficiency ratios could be used to measure how well Crescita Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of July 2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to grow to -0.19. At this time, Crescita Therapeutics' Total Assets are very stable compared to the past year. As of the 22nd of July 2025, Net Tangible Assets is likely to grow to about 22 M, while Other Current Assets are likely to drop 2,850.As of the 22nd of July 2025, Common Stock Shares Outstanding is likely to grow to about 19.3 M, while Net Loss is likely to drop (2.9 M).
Crescita Therapeutics Workforce Comparison
Crescita Therapeutics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 96,168. Crescita Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Crescita Therapeutics Profit Margins
The company has Profit Margin (PM) of (0.17) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.3) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.3.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.46 | 0.4907 |
|
|
Crescita Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Crescita Therapeutics Price Series Summation is a cross summation of Crescita Therapeutics price series and its benchmark/peer.
Crescita Therapeutics Notable Stakeholders
A Crescita Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Crescita Therapeutics often face trade-offs trying to please all of them. Crescita Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Crescita Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Linda Kisa | Corporate Reporting | Profile | |
| Dominic KingSmith | VP Devel | Profile | |
| Francois Lafortune | Executive GM | Profile |
About Crescita Therapeutics Management Performance
The success or failure of an entity such as Crescita Therapeutics often depends on how effective the management is. Crescita Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Crescita management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Crescita management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.14) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.17) | (0.17) |
Crescita Therapeutics Workforce Analysis
Traditionally, organizations such as Crescita Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Crescita Therapeutics within its industry.Crescita Therapeutics Manpower Efficiency
Return on Crescita Therapeutics Manpower
| Revenue Per Employee | 6.5M | |
| Revenue Per Executive | 6.5M | |
| Net Loss Per Employee | 916.7K | |
| Net Loss Per Executive | 916.7K | |
| Working Capital Per Employee | 3.3M | |
| Working Capital Per Executive | 3.3M |
Other Information on Investing in Crescita Stock
Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.